Skip to main content

MJH Life Sciences® acquires Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, expands leadership in dermatology education

Written by Customer Service on . Posted in Mergers And Acquisitions.

CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) — MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, a preeminent CME-certified conference renowned for advancing knowledge in dermatology through the discussion of cutting-edge research. This acquisition reinforces one of MJH Life Sciences’ core pillars: providing impactful educational experiences aimed at improving the care of patients.

The RAD Annual Meeting is known for its revolutionizing approach to dermatology education, including focused congresses in atopic dermatitis, alopecia areata, vitiligo, and eczema. It will be integrated into the multichannel model of MJH Life Sciences and as a CME-certified conference within the legacy meeting portfolio of Physicians’ Education Resource®, LLC. Further, it will be supported by MJH Life Sciences’ extensive dermatology brands, including HCPLive Dermatology and Dermatology Times®.

“As we deepen our commitment to dermatology, the RAD Annual Meeting and its unique forums enable us to expand our educational platform on the cutting-edge of dermatologic research,” said Mike Hennessy Jr., CEO of MJH Life Sciences. “The MJH Life Sciences framework—with its comprehensive CME and media resources—will rapidly expand the reach and impact of the meeting to better improve the care of patients with atopic dermatitis, alopecia areata, vitiligo, or eczema.”

Jonathan I. Silverberg, MD, PhD, MPH, conference chair for RAD, shared enthusiasm for the acquisition. “Collaborating with MJH Life Sciences offers incredible potential to expand our educational programming,” he said. “MJH’s expertise will empower the RAD live and virtual meetings to continue delivering top-tier, evidence-based education that meets the needs of dermatologists globally.”

Aligned with MJH Life Sciences’ growth strategy supported by BDT & MSD Partners, LLC, since 2021, the acquisition deepens MJH’s educational portfolio across diverse health care sectors.

To learn more about RAD and its offerings, please visit Revolutionizing Atopic Dermatitis.

About MJH Life Sciences

MJH Life Sciences is a leading provider of health care content and education, dedicated to improving patient outcomes and advancing the knowledge of health care professionals. With a diverse portfolio of media properties, MJH Life Sciences delivers critical information and educational resources to the pharmaceutical, biotechnology and health care communities. For more information, visit MJH Life Sciences®.

Media Contact
Gary Hagestad
MJH Life Sciences
ghagestad@mjhlifesciences.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.